Craig Gibbs

Craig brings to Asher Bio more than 31 years in the biopharmaceutical industry, including a variety of research, business, and commercial roles, and continues to be passionate about building great teams to enable the translation of scientific innovation into benefits for patients.

Craig currently serves as the C.E.O. and Acting Chairman of the Board of Asher Bio. Also, he serves on the Boards of Directors for Aridis Pharmaceuticals (NASDAQ: ARDS), Inipharm Inc., and the Northern California Chapter of the Leukemia and Lymphoma Society.

Previously Craig was Chief Business Officer at Forty Seven Inc. (NASDAQ: FTSV) and served on the Board of Tobira Therapeutics (NASDAQ: TBRA). Prior to Forty-Seven, Craig spent 21 years at Gilead Sciences in leadership roles, including Vice President of Commercial Strategy, Senior Director of Corporate Development, Senior Director, and Head or 5iology Research, where he contributed to the development, launch, and commercialization of 12 F.D.A. approved drugs.

Before Gilead, Craig spent three years in the Protein Engineering Department at Genentech as a postdoctoral fellow. He has published over 50 scientific articles and is an inventor on three issued patents. He received his Ph.D. n Molecular Biology from the University of Glasgow, Scotland, a B.Sc.(Hons) in Biochemistry from Massey University, New Zealand, and an M.B.A. from Golden Gate University in San Francisco, CA.